Actinogen Medical’s Oversubscribed $3.9M Offer

Actinogen Medical Limited (AU:ACW) has released an update.

Actinogen Medical Limited has successfully completed an oversubscribed $3.9 million entitlement offer, with the raised funds set to advance the XanaMIA trial for Alzheimer’s treatment and general working capital. The offer saw a high demand with applications for additional shares reaching 1.8 times the available amount, indicating strong investor confidence. The new shares and options have been issued, with trading set to begin the following day on the ASX.

For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.